Literature DB >> 32128185

A rare case of acral persistent papular mucinosis.

Joseph Jia-Hong Toh1, Nicholas Seng-Geok Goh1, Ding Yuan Wang1.   

Abstract

In patients with asymptomatic papules of hands and feet, a clinical differential of acral persistent papular mucinosis should be thought of.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  dermatology; mucinosis; myxedematosus; scleromyxedema

Year:  2020        PMID: 32128185      PMCID: PMC7044381          DOI: 10.1002/ccr3.2639

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


INTRODUCTION

Acral persistent papular mucinosis is a very rare subtype of localized lichen myxedematosus. Based on the diagnostic criteria proposed by Rongioletti and Rebora in 2001,1 there are only 35 cases of APPM reported so far.2, 3 We present a 66‐year‐old Chinese man with asymptomatic papules on his hands and wrists, which adequately meet clinical and pathological criteria for acral persistent papular mucinosis.

CASE HISTORY/ EXAMINATION

Our patient complained of 9 months of persistent and asymptomatic skin lesions on his upper limbs, especially on hands and wrist. The lesions appeared spontaneously and progressively enlarged. He denied previous insect bites, injuries, or trauma to the affected sites. There was no relationship with sun exposure. No other family member was affected. He had no past medical history apart from longstanding hyperlipidaemia which was controlled with simvastatin. Physical examination revealed multiple small 3 to 4 mm firm round skin‐colored papules located exclusively on the dorsum of the hands, wrists, and forearms (Figure 1).
Figure 1

(A) Clinical photographs of skin‐colored papules on hands and forearms, (B) Close‐up image of papule

(A) Clinical photographs of skin‐colored papules on hands and forearms, (B) Close‐up image of papule

DIFFERENTIAL DIAGNOSIS, INVESTIGATIONS, AND TREATMENT

Differential diagnoses included papular granuloma annulare, molluscum contagiosum, lichen nitidus, lichen amyloidosus, papular elastorrhexis, and eruptive collagenomas. Punch biopsy specimen from a papule was performed. Histology showed focal spongiosis, lymphocytic exocytosis, and mild perifollicular inflammatory infiltrate with no increased fibroblasts (Figure 2). The upper and middle dermis showed increased mucin deposits which stained positively with Alcian blue. Laboratory studies were normal, showing no evidence of plasma cell dyscrasia, thyroid dysfunction, connective tissue disorders, and human immunodeficiency virus infection. Hepatitis C infection screen was not performed. The patient was diagnosed with acral persistent papular mucinosis. He declined treatment as he had no symptoms.
Figure 2

(A) Increased upper and mid‐dermal mucin deposits are seen (H&E, magnification x20), (B) mucin deposits stain positively with Alcian blue (Alcian blue, magnification x200)

(A) Increased upper and mid‐dermal mucin deposits are seen (H&E, magnification x20), (B) mucin deposits stain positively with Alcian blue (Alcian blue, magnification x200)

OUTCOME AND FOLLOW‐UP

The chronic but benign disease course of acral persistent papular mucinosis was explained to the patient. Given the absence of any systemic involvement and active symptoms, the patient chose to observe his skin for spontaneous resolution. A future follow‐up appointment was offered.

DISCUSSION

Cutaneous mucinoses are heterogeneous disorders in which mucin deposits abnormally in skin. The etiology is unclear. They are classically divided into two groups; (a) primary forms, in which mucin accumulation is the major histologic feature and leads to clinically distinctive lesions and (b) secondary forms, in which mucin accumulation is only an associated finding. Primary cutaneous mucinoses can be divided into degenerative or inflammatory forms and hamartomatous or neoplastic forms. Degenerative or inflammatory primary mucinosis is further subclassified into dermal or follicular types. In 2001, Rongioletti and Rebora proposed a classification for dermal mucinosis.4 It is differentiated into two main groups: generalized form (or scleromyxedema) and localized form (or lichen myxedematosus). The former is associated with systemic disorders which include paraproteinemia, endocrinopathies, autoimmune connective tissue diseases, and hematologic malignancies. The latter has no associations with systemic diseases. The diagnostic criteria of scleromyxedema and lichen myxedematosus are summarized in Table 1. Cases that do not meet criteria for either forms are classified as atypical.
Table 1

Diagnostic criteria of scleromyxedema versus lichen myxedematosus

ScleromyxedemaLichen myxedematosus
Generalized papular eruption and sclerodermoid featuresPapular eruption (or nodules and/or plaques due to confluence of papules)
Microscopic triad (mucin deposition, fibroblast proliferation, fibrosis)Mucin deposition with variable fibroblast proliferation
Monoclonal gammopathyAbsence of monoclonal gammopathy
Absence of thyroid disorderAbsence of thyroid disorder
Diagnostic criteria of scleromyxedema versus lichen myxedematosus The localized variants of lichen myxedematosus are further subdivided into four distinct subtypes, including (a) a discrete papular form, (b) acral persistent papular mucinosis, (c), cutaneous mucinosis of infancy, and (d) a pure nodular form. The first case of acral persistent papular mucinosis was reported by Rongioletti et al as a subtype of lichen myxedematosus in 1986.5 In acral persistent papular mucinosis, small papules are localized exclusively on dorsum of hands, wrists, and extensor aspects of distal forearms with no other clinical or laboratory manifestations. Lesions may persist and increase in number slowly with time. Histologically, Alcian blue staining demonstrates upper dermal mucin accumulation with collagen fibers separation from hyaluronic acid deposition. To date, only 35 cases of acral persistent papular mucinosis have been reported.2, 3 It is reported to have a female predominance, and mean age at onset was 42.9 ± 15.9 years.2 The possible association with solid organ or hematological malignancies remains unclear. As patients with acral persistent papular mucinosis are generally asymptomatic, treatment is rarely necessary. For patients who request treatment due to cosmetic concerns, topical corticosteroids, calcineurin inhibitors, liquid nitrogen, electrocoagulation, laser ablation, and surgical excision have been reported as successful therapeutic options.2, 3, 6 We report another case of acral persistent papular mucinosis. This diagnosis should be considered in patients with acral papules. It is appropriate to exclude other systemic involvement when mucin accumulation is confirmed.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

JJHT and DYW: prepared manuscript. NG: described dermatopathology input.
  6 in total

1.  Acral persistent papular mucinosis: a new entity.

Authors:  F Rongioletti; A Rebora; F Crovato
Journal:  Arch Dermatol       Date:  1986-11

2.  Acral persistent papular mucinosis: a case report and literature review.

Authors:  Di-Qing Luo; Liang-Cai Wu; Jun-Hua Liu; Hai-Yan Zhang
Journal:  J Dtsch Dermatol Ges       Date:  2010-12-02       Impact factor: 5.584

3.  Cutaneous mucinoses: microscopic criteria for diagnosis.

Authors:  F Rongioletti; A Rebora
Journal:  Am J Dermatopathol       Date:  2001-06       Impact factor: 1.533

Review 4.  Acral persistent papular mucinosis.

Authors:  Jocelyn E Harris; Stephen M Purcell; Thomas D Griffin
Journal:  J Am Acad Dermatol       Date:  2004-12       Impact factor: 11.527

Review 5.  Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema.

Authors:  F Rongioletti; A Rebora
Journal:  J Am Acad Dermatol       Date:  2001-02       Impact factor: 11.527

6.  Acral papular mucinosis: a new case of this rare entity.

Authors:  María Encarnación Gómez Sánchez; Fernando de Manueles Marcos; Maria Luisa Martínez Martínez; Roberto Vera Berón; Jose Manuel Azaña Défez
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.